

Overview of the Role of Clinical Innovations, Quality Improvement and Cost Containment in Healthcare

National Congress on Healthcare Clinical Innovations, Quality Improvement and Cost Containment Sponsored by The Bipartisan Policy Center and The Aspen Institute

October 26, 2011





Sam Nussbaum, M.D.
Executive Vice President, Clinical Health
Policy and Chief Medical Officer



A Tale of Health Care in Our Nation

"It was the best of times...

Unprecedented advances in medical technology, treatments, and pharmaceuticals can improve population health







It was the worst of times..."

The state of public health, unsustainable health care costs, the quality of medical care delivered and access to services challenge clinical care and overall health

From "A Tale of Two Cities"
By Charles Dickens



Health Care Burning Platform: A System in Need of Change

Affordability of Health Care

Quality / Safety


Critical Issues in Health Care


The Uninsured / Access to Care


State of Public Health



Health Expenditures








2008 version of the National Health Expenditures (NHE) released in January 2010

Kaiser/HRET Survey of Employer-Sponsored Health Benefits, 2001-2011.



Healthcare Costs are Concentrated






Discovery and Innovation




Statins reduce cardiac deaths





HIV Medications reduce AIDS deaths






Discovery and Innovation



Improved screening and drugs

Cancer in the United States, 1990-2007: Survival Rising, Mortality Decreasing



Data from the National Cancer Institute on estimated number of cancer survivors and age-adjusted cancer deaths per 100,000 people



Personalized Medicine





Discovery/Invention and Clinical Care Innovation





Surgical Checklists





Evidence-based decision-making

Payment Reform





Genomics and Proteomics


Specialty drug treatments





Academia, Government and Industry Research and Development

- 6 of the top 10 companies in global R&D expenditures are biopharmaceutical companies
- Over 2/3 of US patents in biopharma were issued to USbased life science companies
- U.S. leads the world in drug discovery: 2/3 new drugs in last 10 years from U.S.; currently 82% of world's biopharma pipeline from US



"There is an ecosystem of science and biotechnology. Public organizations, patient organizations, universities, Congress, FDA, all of this is an ecosystem that is envied in the rest of the world." E. Zerhouni, Director of NIH

Sources: ¹Burrill & Company, analysis for PhRMA, 2005–2009 (Includes PhRMA research associates and nonmembers) in PhRMA, "Profile 2008, Pharmaceutical Industry;" PhRMA, "PhRMA Annual Membership Survey," 1996-2009; ²Adapted from E. Zerhouni, Presentation at Transforming Health: Fulfilling the Promise of Research, 2007; ³NIH Office of the Budget, "FY 2009 President's Budget Request Tabular Data", http://officeofbudget.od.nih.gov/ui/2008/tabular%20data.pdf



Increasing Specialty Drug Development and Associated Costs

- Highly sophisticated protein structures derived from recombinant DNA technologies, most often given by injection or infusion.
- Specialty pharmaceuticals now represent 24% of all drug costs, projected to 40% by 2014
- Expenditures exceed \$73 billion annually, rising at twice the rate of conventional drugs
- Average cost per prescription is nearly \$2,000, with annual treatment costs ranging from \$5,000 to \$350,000
- Over 600 specialty drugs in development for 100 different diseases, including
 - 250 for cancer,
 - 160 for infectious diseases,
 - 60 for autoimmune diseases,
 - 35 for HIV/AIDS



The Architecture for Innovation

Improved Health Care and Lower Costs

Payment Innovation Care Health Innovation Innovation

Health Information



Payment Innovation: Improving Value and Affordability

Old Model:

Rate increases not tied to value

Reward unit cost

Inadequate focus on outcomes

Payment sometimes aligned with quality

New Model:

Rate increases tied only to quality, safety, and value

Align all payment with quality

Lower cost without adversely affecting outcomes

Improve quality



Hospital Quality: Q-HIP® Hospital Quality Program

Q-HIP® Hospital Pay-for-Performance rewards quality, safety, outcomes, and patient satisfaction

Patient Safety Section (35% of total Q-HIP® Score)

- Joint Commission National Patient Safety Goals
- Computerized Physician Order Entry (CPOE)
 System
- ICU Physician Staffing (IPS) Standards
- NQF Recommended Safe Practices
- IHI 5 Million Lives Campaign ADE Medication Reconciliation and WHO Surgical Safety Checklist
- CDC/APIC Flu and Pneumonia Vaccine Guidelines
- NQF Perinatal Measures

Member Satisfaction Section (10% of Total Q-HIP® Score)

• H-CAHPS Survey Results

Patient Health Outcomes Section (55% of total Q-HIP® Score)

PCI Indicators

• 5 ACC-NCDR/Indicators for Cardiac Catheterization/PCI

Joint Commission/CMS Nat'l Hospital Quality Measures

- Acute Myocardial Infarction (AMI) Indicators
- Heart Failure (HF) Indicators
- Pneumonia (PN) Indicators
- Surgical Care Improvement Project (SCIP)

NSC Indicators

4 JC/NQF Nursing Sensitive Care Indicators

CABG Indicators

• 5 STS Coronary Artery Bypass Graft (CABG)
Measures



California Patient Safety First










Excellence Through Leadership & Collaboration



California Patient Safety: 2009-2010





Highlights of PCMH Results





- Quality improvement in nearly all diabetes measures
- 3.6% decrease in acute IP admissions per 1000 per year
- 6.1% decrease in total ER visits per 1000 per year
- 1.3% increase in persistent medication usage



NEW YORK


- IP rate per 1000 between 12% 23% lower for PCMH providers
- ER rate per 1000 between 11% 17% lower for PCMH providers
- Total medical and Rx cost for PCMH members was 14.5% lower than for members seeing non-PCMH providers



Improving Primary Care: Comprehensive Primary Care Initiative

- CMS led private-public initiative testing a primary care service delivery and payment model in 5-7 locations
 - Service delivery model:
 - Risk-stratified Care Management
 - Access and Continuity
 - Planned Care for Chronic conditions and Preventive Care
 - Patient and Caregiver Engagement
 - Coordination of Care
 - Payment Model: monthly care management fee to primary care practices for FFS Medicare beneficiaries; potential to share savings in 2-4 years
 - Aligned payment from private insurers







ACOs: The Race to Value-Based Care



Key Principles for the Race:

- Primary Care is central
- Commit to evidence-based medicine
- Information at the point of care
- •Focus on health, prevention, risk reduction for chronic illness
- Coordination of care

Concerns Along the Way:


- Attribution
- Overuse of supply sensitive care increases revenue;
 optimized FFS revenue model
- Payment shifting to private sector; will gain sharing overpower FFS
- Acquisition of specialty practices





CareMore: Care Innovation

- Care Centers provide a "Healthy Start" initial evaluation and integrated care that offers personalized health planning
- Specialists intensively manage chronically ill members: approximately 20% of members that account for 60% of medical costs
- Biometric monitoring





Improved Outcomes for Chronic Diseases

Diabetes



Result

7.08 average HbA1c for those attending diabetes clinic

End Stage Renal Disease



Result

50% reduction in hospital admission rate in 5 months

Congestive Heart Failure




Result


56% reduction in hospital admission rate in 3 months



Preventing Avoidable Re-Hospitalizations



WellPoint 30-Day Re-Hospitalizations



Causes


- No scheduled follow-up
- Poor medication compliance
- Unclear discharge instructions

Intervention


- Identify patients with greatest opportunity to impact
- Create discharge plan with patient during hospital stay
- Nurses call to schedule and coordinate follow-up care



Advanced Imaging: Increased Utilization, Costs and Safety Risk



Imaging Safety: Coronary CT



- Commercial market average annual growth rate = 15%
- Medicare imaging 2000-2006
 - Costs per Medicare beneficiary increased 52%
 - Advanced imaging grew at twice the rate of standard imaging
 - Average annual growth rate = 13%
- Unnecessary radiology services increase radiation exposure risks
- WellPoint program: imaging trend 0%-5%



Personalizing Care Management

Case Mgmt via Web Cam





Wireless Biometrics








Potential of Artificial Intelligence

Artificial Intelligence offers unique value for clinical input

- Ability to manage large amounts of unstructured data, even in natural language form (e.g. a normal journal article or an MD clinical summary)
- Influence evidence-based care by providing real-time, value-added, actionable insights to clinicians
- Unique capability to learn, train, and optimize its own algorithms from historical decisions
- Probability based diagnosis and treatment recommendations
- Defined by Evidence Based Medicine
- Streamlined authorization/approval of procedures and treatment

MEDLINE-indexed articles published per year



- Over 21 million articles in Medline
- Almost 1 million new articles per year
- → 1.6 billion searches in 2010



IBM Watson has the potential to help doctors make better decisions—faster

Potential Knowledge Sources May Include:

- Latest medical research
- Population health info
- Patient medical history
- Lab results
- Data analysis
- Complex treatment protocols



Our data

Extensive provider networks



Analyzes millions of pages/second

Targeted treatment options

IBM Watson technology to assist by analyzing data and providing responses



IBM Watson





The Need for Evidence-Based Medicine

History: Bone Marrow Transplant

- Bone marrow transplantation (BMT) for breast cancer entered medical market in the 1980s before meaningful effectiveness studies were done
- Between 1988-1998, 30,000 procedures and \$5 Billion in medical costs
- Congress and States enacted mandatory coverage legislation in 1994
- 1999 research showed no difference in survival and lower quality of life
- Delayed research and introduction of promising therapies


Today: HER2 Genetic Testing

- 215,000 new breast cancer cases annually; 25-30% of women with breast cancer express the HER2 protein
- Trastuzumab (Herceptin®) is a recombinant DNA monoclonal antibody that targets tumor cells that over express the HER2 protein
- In 2005, two new major clinical trials expanded indications for this biotechnology



Emerging Medical Technologies and Comparative Effectiveness

Diagnosis and Treatment of Prostate Cancer is Controversial



Comparative effectiveness can assess outcomes, quality of life, and survival



Back Pain Treatment Options, Risks, and Benefits

Facts on Back Pain

- 9 of 10 Americans experience back pain
- #1 cause of lost work productivity
- \$90B spent nationally on treatment
- Most pain resolves within 6 weeks independent of treatment

Study of 172,000 Anthem Members in 6 States

- 1,000 surgeries during first 6 weeks
- 35,000 imaging procedures within first 6 weeks
- Care dependent on initial treating physician

Value and Benefits

- Collaboration with American Academy of Family Physicians
- New payment models including bundling of payments
- Educate members/physicians on treatment options











WellPoint Position: CER Promotes Value and Innovation

Collaboration amongst health care system stakeholders is central to making CER work

- Address unsustainable health care costs
 - Limited resources threaten innovation
- Help patients choose more effective treatments
 - Fewer unnecessary services = health system savings
- Quality first, then affordability
 - Superior treatments deserve our nation's investment
- Comparable treatments should be chosen on value
- Selectively effective personalized treatments should be managed by physicians and patients
- Remove inappropriate/ineffective treatments

SUPERIOR

COMPARABLE

PERSONALIZED

INEFFECTIVE



Closing Gaps in Evidence-Based Care

Report of: Adam

Birth Date: February 28, 1946

Service/Prescription

Member ID: 00123456-01 Group Number: GRX 123678

Your Medical & Prescription Claims

Your recent medical and prescription claims as of

May 23, 2008

Suggestions for You

Suggestions are based on your available claims as of

May 23, 2008

Visits				
05/23/08	Office Visit	 	Lynn, Samuel F.	\$85.00
05/17/08	Office Visit	 	Wilson, Michelle L.	\$85.00
05/15/08	Office Visit	 	Lynn, Samuel F.	\$85.00
04/12/08	Office Visit	 	Jones, Terry M.	\$85.00
02/02/08	Office Visit	 	Wilson, Michelle L.	\$195.00

Qty Days Doctor/Prescriber(*)

Mercy Hospital - Rad

\$854.35

Prescriptions

01/15/08

Date

Frescript	10115				
05/01/08	Metformin - 500 mg	30	30	Jones, Terry M.	\$15.50
03/23/08	Metformin - 500 mg	30	30	Wilson, Michelle L.	\$46.50
02/10/08	Lipitor - 20 mg	30	30	Lynn, Samuel F.	\$85.95
01/18/08	Lipitor - 20 mg	30	30	Lynn, Samuel F.	\$85.95
03/28/08	Accupril - 20 mg	60	30	Lynn, Samuel F.	\$66.99
02/18/08	Accupril - 20 mg	60	30	Lynn, Samuel F.	\$66.99
01/12/08	Accupril - 20 mg	60	30	Lynn, Samuel F.	\$66.99
02/12/08	Nexium - 20 mg	30	30	Lynn, Samuel F.	\$115.60
01/10/08	Nexium - 20 mg	30	30	Lynn, Samuel F.	\$115.60
Other Me	dical Services				
05/23/08	Cholesterol Panel			LabCorp Laboratories	\$110.40
04/26/08	Medical Equipment			Lynnwood Medical Mart	\$198.00
03/28/08	Ambulatory ER Visit			St. Lucy's Hospital ER	\$766.50
03/28/08	Metabolic Panel			LabCorp Laboratories	\$110.40
02/04/08	CT X-Ray, Sinuses			Radiology Assoc SFSL	\$854.35



Ask your doctor about blood thinner medication [10235] *

Your medical claims show you have a heart condition called atrial fibrillation, and your prescription claims show you are not taking a blood thinner medication. Atrial fibrillation is an uneven heartbeat that can cause blood clots and strokes. Blood thinners can prevent blood clots and lower your risk of a stroke. Ask your doctor soon if you should take a blood thinner.



Keep taking Metformin as directed [119] *

Your prescription claims show you take metformin. Although you recently refilled your prescription, your claims show you are not refilling it as often as you should. This drug can help lower your risk of heart disease, stroke and blindness. If you think your medication is not helping you, or if you are worried about cost or side effects, talk to your doctor soon. Keep taking metformin as directed until you talk to your doctor.



Save \$396 - Ask your doctor about switching from Accupril [3582]*

Your prescription claims show you take Accupril. You can save money if you take quinapril, a generic drug that is as safe and effective as Accupril. Ask your doctor if quinapril is right for you.

Drug Name	Your Cost	Your Annual Cost	You Save
Accupril - 20 mg	\$40	\$480	
Quinapril - 20 mg	\$ 7	\$ 84	\$396

^{**} This amount is the total paid by you and your health plan.




CT X-Ray, Sinuses



^{*} Doctor/Prescriber listed may be another name from that medical office/practice.



Anthem Care Comparison: Cost and Quality Information for Consumers





Anthem Care Comparison: Variance in Cost for Spinal Fusion

This report compares providers within 5 miles of Washington, DC for Spinal Fusion (Posterior). This is just one of several sources you should consult to select a service provider; always consult your physician about what decision is right for you.

Name	Location	Distance	Typical Cost Low	Typical Cost High	Number of Services/Year	Blue Distinction Center
▼	▼	ਯ	▼	₩	₩.	▼
George Wash Univ	900 23rd St NW Washington, DC 20037 202-715-4000	2 mi (<u>map</u>)	\$41,805	\$47,030	N/A	Blue Distinction® Spine Surgery
Washington Hospital Center	216 Michigan Ave NW Washington, DC 20017 202-877-7000	2 mi (<u>map</u>)	\$41,805	\$47,030	N/A	
Georgetown Univ	3800 Reservoir Rd NW Washington, DC 20007 202-444-1400	3 mi (<u>map</u>)	\$62,707	\$67,933	N/A	
Montgomery General Hospital	18101 Prince Philip Dr Olney, MD 20832 301-774-8882	17 mi (<u>map</u>)	\$38,807	\$43,119	N/A	Blue Distinction® Spine Surgery
Fair Oaks Hospital	3600 Joseph Siewick Dr Fairfax, VA 22033 703-391-3600	19 mi (<u>map</u>)	\$50,213	\$54,579	143	Blue Distinction* Spine Surgery
Baltimore Washington Medical Center	301 Hospital Dr Glen Burnie, MD 21061 410-787-4000	27 mi (<u>map</u>)	\$25,921	\$29,624	N/A	Blue Distinction® Spine Surgery
Saint Agnes Hospital	900 Caton Ave Baltimore, MD 21229 410-368-6000	31 mi (<u>map</u>)	\$47,350	\$51,654	N/A	Blue Distinction® Spine Surgery
Mercy Medical Center Inc	301 Saint Paul St Baltimore, MD 21202 410-332-9000	34 mi (<u>map</u>)	\$34,436	\$38,741	N/A	Blue Distinction® Spine Surgery
University of Maryland Medical Center	22 S Greene St Baltimore, MD 21201 800-373-4111	34 mi (<u>map</u>)	\$38,741	\$43,045	N/A	Blue Distinction® Spine Surgery



National Drug, Vaccine, and Biologic Safety









34 million members' claims, pharmacy, and laboratory data enables population safety and public health research

- FDA Vaccine and Biologics Safety Surveillance
- FDA Sentinel Initiative Coordinating Center
- FDA Drug Safety Surveillance
- National Institutes of Health Challenge Grant
- HHS Contract to Monitor National H1N1 Vaccine Safety



Vast Possibility with Creativity, Passion, and Tenacity

